[go: up one dir, main page]

Notni, 2023 - Google Patents

RSC Medicinal Chemistry

Notni, 2023

View PDF
Document ID
13693261992975666678
Author
Notni J
Publication year

External Links

Snippet

Multimerization is an established strategy to design bioactive macromolecules with enhanced avidity, which has been widely employed to increase the target-specific binding and uptake of imaging probes and pharmaceuticals. However, the factors governing the …
Continue reading at pdfs.semanticscholar.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents

Similar Documents

Publication Publication Date Title
JP7378449B2 (en) cartilage homing peptide
US11446356B2 (en) Peptides and related compositions and methods
Shen et al. Positron emission tomography imaging of drug‐induced tumor apoptosis with a caspase‐triggered nanoaggregation probe
Maschauer et al. 18F-Glyco-RGD peptides for PET imaging of integrin expression: efficient radiosynthesis by click chemistry and modulation of biodistribution by glycosylation
JP5237283B2 (en) Cyclopeptide derivatives as imaging agents for integrins
Liu et al. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors
Pagel Inverse electron demand Diels–Alder (IEDDA) reactions in peptide chemistry
CN108026144B (en) 18F-labeled inhibitors of Prostate Specific Membrane Antigen (PSMA) and their use as imaging agents for prostate cancer
Quigley et al. Complexity of αvβ6-integrin targeting RGD peptide trimers: emergence of non-specific binding by synergistic interaction
Seward et al. Peptide-mediated cellular uptake of cryptophane
Liu et al. 90Y and 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy
Pettit et al. Isolation and structure of the human cancer cell growth inhibitory cyclodepsipeptide dolastatin 16, 1
Pilkington-Miksa et al. Design, synthesis, and biological evaluation of novel cRGD–paclitaxel conjugates for integrin-assisted drug delivery
Guo et al. Design and evaluation of new Tc-99m-labeled lactam bridge-cyclized alpha-MSH peptides for melanoma imaging
Singh et al. Dimerization of a phage-display selected peptide for imaging of αvβ6-integrin: two approaches to the multivalent effect
JP2018531243A6 (en) 18F-tagged inhibitor of prostate specific membrane antigen (PSMA) and its use as an imaging agent for prostate cancer
Roxin et al. Conformational modulation of in vitro activity of cyclic RGD peptides via aziridine aldehyde-driven macrocyclization chemistry
Miao et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression
Kapp et al. N-Methylation of iso DGR peptides: discovery of a selective α5β1-integrin ligand as a potent tumor imaging agent
Bianchini et al. 125I-Radiolabeled morpholine-containing arginine–glycine–aspartate (RGD) ligand of αvβ3 integrin as a molecular imaging probe for angiogenesis
Harris et al. Structure− activity relationships of 111In-and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents
Brandt et al. Enzymological characterization of 64Cu-labeled neprilysin substrates and their application for modulating the renal clearance of targeted radiopharmaceuticals
Cantorias et al. MO tripeptide diastereomers (M= 99/99mTc, Re): models to identify the structure of 99mTc peptide targeted radiopharmaceuticals
Guo et al. Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide
Notni RSC Medicinal Chemistry